- Shopping Bag ( 0 items )
Doody's Review ServiceReviewer: Raj Tummala, MD (Wyeth Pharmaceuticals)
Description: This is an annual update of recent clinical trials and advances in the management of neurologic and neuropsychiatric disorders.
Purpose: The purpose is to provide a comprehensive review of the latest advances in clinical trials of neurologic and psychiatric disorders.
Audience: This is primarily targeted at neurologists, psychiatrists, drug developers, translational scientists, and anyone involved in research in the neurosciences.
Features: This volume focuses on both psychopharmacological management of neuropsychiatric disorders and nondrug treatments. All of the articles are authored by experts in the respective areas and are chosen by the editorial board. This edition captures advances in migraine, Parkinson disease, stroke, epilepsy, multiple sclerosis, Alzheimer's disease, traumatic brain injury, depression, and schizophrenia. It also covers the influence of these clinical trial results on practice guidelines and advances in trial methodologies. The topics are presented in a general consistent format that describes the trial methodology, outcome measures, and efficacy and safety results. Interesting in each chapter is the translation of the results to clinical practice and their impact on evidence-based medicine. The authors also discuss the unique aspects of the trial and the trial methodologies and their regulatory implications. Information is augmented with tables, graphs, and charts. Each chapter has an extensive reference section.
Assessment: The third edition captures the important progress and advances over the last year in neurological and psychiatric disorders. This is a nice series for any neuroscience researcher interested in clinical trial updates.